BioPharmSignal logoBioPharmSignal

Biotech News

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Protagenic Therapeutics (PTIX)Protagenic TherapeuticsEarnings

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023

Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portion

Plans to enroll final two out of five cohorts into the single dose portion of the Phase 1 trial within the next...

Related news

BCLIBrainstorm Cell Therapeutics Inc.2026-08-14 20:00 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

ADXNAddex Therapeutics2026-06-25 05:00 EST

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

ADXNAddex Therapeutics2026-06-22 05:00 EST

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

IKTInhibikase Therapeutics2026-08-11 20:01 EST

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

AXSMAxsome2026-08-10 11:00 EST

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

AXSMAxsome2026-07-14 11:00 EST

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

View all latest news

Protagenic Therapeutics

Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric and stress-related disorders. Its story is built around the idea that peptide-based or related approaches can address difficult CNS conditions.

Recent company news

PTIXProtagenic Therapeutics2026-05-19 08:15 EST

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

PTIXProtagenic Therapeutics2026-04-23 08:15 EST

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

PTIXProtagenic Therapeutics2026-03-17 08:00 EST

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

PTIXProtagenic Therapeutics2026-03-10 08:00 EST

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

PTIXProtagenic Therapeutics2025-12-09 08:46 EST

Results from Phase 1 Multiple-Dose Study of PT00114

Stock data

Close
0.80 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States